Astellas PharmaALPMF 73 PB Ratio is 2.00 as of Jun. 25, 2026, which is 14% below its 10-year median of 2.32. GuruFocus rates ALPMF with a GF Score™ of 73/100 and a GF Value™ of $14.18 (Fairly Valued). The stock has 4 warning signs investors should review. Among 922 Drug Manufacturers companies, Astellas Pharma ranks worse than 54.99% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-25), Astellas Pharma's share price is $12.85. Astellas Pharma's Book Value per Share for the quarter that ended in Mar. 2026 was $6.43. Hence, Astellas Pharma's PB Ratio of today is 2.00.
The historical rank and industry rank for Astellas Pharma's PB Ratio or its related term are showing as below:
ALPMF'
s PB Ratio Range Over the Past 10 Years
Min: 1.5 Med: 2.32 Max: 3.05
Current: 1.85
During the past 13 years, Astellas Pharma's highest PB Ratio was 3.05. The lowest was 1.50. And the median was 2.32.
ALPMF's PB Ratio is ranked worse than 54.99% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.855
vs ALPMF: 1.85
During the past 12 months, Astellas Pharma's average Book Value Per Share Growth Rate was 20.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 6.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 5.20% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 5.20% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Astellas Pharma was 10.90% per year. The lowest was 1.10% per year. And the median was 4.25% per year.
Back to Basics: PB Ratio
Astellas Pharma (OTCPK:ALPMF) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Astellas Pharma PB Ratio Related Terms
Astellas Pharma PB Ratio Historical Data
* Premium members only.
The historical data trend for Astellas Pharma's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Astellas Pharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Astellas Pharma PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where Astellas Pharma's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Astellas Pharma's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Astellas Pharma (ALPMF) has a PB Ratio of 2.00 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Astellas Pharma and its competitors. This is 14% below median its historical median of 2.32. Over the past decade, Astellas Pharma's PB Ratio has ranged from 1.50 to 3.05. According to the industry distribution chart, Astellas Pharma ranks #507 out of 922 companies in the Drug Manufacturers industry, placing it in the top 55%.
Is Astellas Pharma's PB Ratio too high?
Astellas Pharma's current PB Ratio of 2.00 is 14% below median its 10-year median of 2.32. Over the past 10 years, this metric has ranged from a low of 1.50 to a high of 3.05. The Drug Manufacturers industry median PB Ratio is 1.86. Astellas Pharma's value of 2.00 is 7.8% above this industry median. Based on the distribution chart, Astellas Pharma ranks #507 out of 922 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Astellas Pharma has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Astellas Pharma's PB Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Astellas Pharma ranks #507 out of 922 companies for PB Ratio. This places Astellas Pharma in the lower half of its industry. The industry median PB Ratio is 1.86. Astellas Pharma's value of 2.00 is 7.8% above this benchmark. Historically, Astellas Pharma's own PB Ratio has ranged from 1.50 to 3.05 over the past decade. While the company's 10-year median is 2.32 vs. the industry median of 1.86, Astellas Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.86, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Astellas Pharma's current PB Ratio of 2.00 is 7.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Astellas Pharma and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Astellas Pharma's current PB Ratio is 2.00, which is 14% below median its own 10-year median of 2.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astellas Pharma stock overvalued right now?
Based on GuruFocus' analysis, Astellas Pharma (ALPMF) is currently considered Fairly Valued. The stock's GF Value™ is $14.18, compared to a current price of $12.85 — trading 9.4% below its estimated fair value. The current PB Ratio is 2.00, which is 14% below median its 10-year median of 2.32 and 7.8% above the Drug Manufacturers industry median of 1.86. Astellas Pharma's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Astellas Pharma (ALPMF), the current PB Ratio is 2.00 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Astellas Pharma (ALPMF) Overvalued in 2026?
Based on GuruFocus' analysis, Astellas Pharma stock appears to be undervalued.
The current stock price of $12.85 is trading 9.4% below its estimated GF Value™ of $14.18.
GuruFocus considers Astellas Pharma to be Fairly Valued.
Key valuation signals for ALPMF:
PB Ratio: 2.00 (14% below median its 10-year median of 2.32)
GF Value™: $14.18 vs. price of $12.85 (9.4% below fair value)
Industry Position: 7.8% above the Drug Manufacturers median (#507 of 922)
No single metric tells the full story. See the ALPMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
73GF Score
Get the complete analysis for ALPMF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALPMF has been successfully added to your 
